This application requests Cancer Center Support Grant funding for the Holden Comprehensive Cancer Center (HCCC) at the University of Iowa. This is the second CCSG competitive renewal for the HCCC. The HCCC functions administratively as a matrix Cancer Center with 189 Center members from six colleges and 36 departments across the University. It leverages the resources and expertise provided by the medical center and across the University to support and strengthen transdisciplinary cancer research. The HCCC has extensive support from both the institution and via private support. The members of the HCCC have $74.2 million in total annual cancer-related, peer-reviewed, external research support. Of this, over $20.4 million comes from the NCI. The HCCC is organized into six research programs that are each designed to be translational in nature. Together they encompass a broad spectrum of strength in basic laboratory, clinical and population research. These programs are 1) Cancer Immunology &Immunotherapy, 2) Cancer Signaling and Experimental Therapeutics, 3) Free Radical Cancer Biology, 4) Tumor Imaging, 5).Cancer Epidemiology, and 6) Cancer Genomics and Cell Growth. In addition to the Administrative Core, the HCCC supports eleven shared resources including: 1) DNA, 2) Gene Transfer Vector, 3) Radiation and Free Radical Research, 4) Flow Cytometry, 5) Central Microscopy Research Facility, 6) Small Animal Imaging, 7) Tissue Procurement 8) Bioinformatics, 9) Population Research, 10) Biostatistics, and 11) Clinical Trials Support. Through these programs and cores, and an effective organizational structure, the HCCC enhances interactions, supports collaborations, and sets the direction of future cancer research activities at the HCCC.

Public Health Relevance

The Cancer Center Support Grant supports the infrastructure of the Holden Comprehensive Cancer Center. This infrastructure allows the Center to foster excellence in research across a broad spectrum of scientific areas relevant to cancer, and translate those advances to the clinic with the goal of reducing the morbidity and mortality of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA086862-14
Application #
8640082
Study Section
Subcommittee G - Education (NCI)
Program Officer
Silkensen, Shannon M
Project Start
2000-07-14
Project End
2016-03-31
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
14
Fiscal Year
2014
Total Cost
$2,126,551
Indirect Cost
$718,483
Name
University of Iowa
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Monga, Varun; Maliske, Seth M; Kaleem, Hassan et al. (2018) Discrepancy between treatment goals documentation by oncologists and their understanding among cancer patients under active treatment with chemotherapy. Eur J Cancer Care (Engl) :e12973
Swami, Umang; Lenert, Petar; Furqan, Muhammad et al. (2018) Atezolizumab after Nivolumab-Induced Inflammatory Polyarthritis: Can Anti-PD-L1 Immunotherapy Be Administered after Anti-PD-1-Related Immune Toxicities? J Thorac Oncol 13:e102-e103
Seaman, Aaron T; Dukes, Kimberly; Hoffman, Richard M et al. (2018) The complicated 'Yes': Decision-making processes and receptivity to lung cancer screening among head and neck cancer survivors. Patient Educ Couns 101:1741-1747
Shields, Anthony F; Jacobs, Paula M; Sznol, Mario et al. (2018) Immune Modulation Therapy and Imaging: Workshop Report. J Nucl Med 59:410-417
Vijapura, Charmi; Yang, Limin; Xiong, Jinhu et al. (2018) Imaging Features of Nonmalignant and Malignant Architectural Distortion Detected by Tomosynthesis. AJR Am J Roentgenol 211:1397-1404
Brooks, Nathan A; Boland, Riley S; Strigenz, Michael E et al. (2018) Nongenitourinary complications associated with robot-assisted laparoscopic and radical retropubic prostatectomy: A single institution assessment of 1,100 patients over 11 years. Urol Oncol 36:501.e9-501.e13
Sandgren, Jeremy A; Deng, Guorui; Linggonegoro, Danny W et al. (2018) Arginine vasopressin infusion is sufficient to model clinical features of preeclampsia in mice. JCI Insight 3:
Jiang, Cheng-Fei; Shi, Zhu-Mei; Li, Dong-Mei et al. (2018) Estrogen-induced miR-196a elevation promotes tumor growth and metastasis via targeting SPRED1 in breast cancer. Mol Cancer 17:83
Moss, Jennifer L; Xiao, Qian; Matthews, Charles E (2018) Patterns of cancer-related health behaviors among middle-aged and older adults: Individual- and area-level socioeconomic disparities. Prev Med 115:31-38
Gu, Chunyan; Jing, Xuefang; Holman, Carol et al. (2018) Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma. BMC Cancer 18:1152

Showing the most recent 10 out of 1080 publications